ES2195049T3 - Analogos de vitamina d3 fluorados. - Google Patents
Analogos de vitamina d3 fluorados.Info
- Publication number
- ES2195049T3 ES2195049T3 ES97107868T ES97107868T ES2195049T3 ES 2195049 T3 ES2195049 T3 ES 2195049T3 ES 97107868 T ES97107868 T ES 97107868T ES 97107868 T ES97107868 T ES 97107868T ES 2195049 T3 ES2195049 T3 ES 2195049T3
- Authority
- ES
- Spain
- Prior art keywords
- sub
- link
- hydrogen
- double link
- fluoroalquilo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 title abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract 13
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical class [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 7
- 239000001257 hydrogen Substances 0.000 abstract 7
- 208000001132 Osteoporosis Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C401/00—Irradiation products of cholesterol or its derivatives; Vitamin D derivatives, 9,10-seco cyclopenta[a]phenanthrene or analogues obtained by chemical preparation without irradiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
- C07F7/1804—Compounds having Si-O-C linkages
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Nutrition Science (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
LOS NUEVOS ANALOGOS DE VITAMINA D3 DE FORMULA I DONDE: X ES (H,H) O = CH{SUB,2}; R{SUB,1} Y R{SUB,2} SON, INDEPENDIENTEMENTE ENTRE SI, HIDROGENO, (C{SUB,1} OROALQUILO, O R{SUB,1} Y R{SUB,2} JUNTO CON C C{SUB,3} B,1} Y R{SUB,2} JUNTOS FORMAN = CH{SUB,2}; R{SUB,3} Y R{SUB,4} SON, INDEPENDIENTEMENTE ENTRE SI, (C{SUB,1} C{SUB,4}) ALQUILO O FLUOROALQUILO, O R{SUB,3} Y R{SUB,4} JUNTO CON C UN (C{SUB,3} ES UN ENLACE SENCILLO O UN DOBLE ENLACE; Y B ES UN DOBLE ENLACE O UN TRIPLE ENLACE; EXCEPTO QUE: (I) CUANDO X ES = CH{SUB,2}, R{SUB,3} Y R{SUB,4} SON CADA UNO DE ELLOS CF{SUB,3}, A ES UN DOBLE ENLACE Y UNO DE R{SUB,1} O R{SUB,2} ES HIDROGENO, ENTONCES EL OTRO R{SUB,1} O R{SUB,2} NO PUEDE SER CH{SUB,3}; (II) CUANDO X ES = CH{SUB,2}, R{SUB,3} Y R{SUB,4} SON CADA UNO DE ELLOS UN (C{SUB,1} ,2} ES HIDROGENO, ENTONCES R{SUB,1} NO PUEDE SER CH{SUB,3}; (III) CUANDO X ES = CH{SUB,2}, R{SUB,3} Y R{SUB,4} SON CADA UNO DE ELLOS UN (C{SUB,1} B,3}; (IV) CUANDO X ES = CH{SUB,2}, UNO DE R{SUB,3} O R{SUB,4} ES UN CF{SUB,3}, A ES UN DOBLE ENLACE, R{SUB,1} ES CH{SUB,3} Y R{SUB,2} ES HIDROGENO, ENTONCES EL OTRO R{SUB,3} O R{SUB,4} NO PUEDE SER CH{SUB,3}; Y (V) CUANDO X ES (H,H), R{SUB,3} Y R{SUB,4} SON CADA UNO DE ELLOS CF{SUB,3}, A ES UN DOBLE ENLACE, B ES UN TRIPLE ENLACE Y R{SUB,2} ES HIDROGENO, ENTONCES R{SUB,1} NO PUEDE SER CH{SUB,3}, Y LOS COMPUESTOS DE LA FORMULA I ANTERIOR DONDE: X ES (H,H) O = CH{SUB,2}; R{SUB,1} Y R{SUB,2} SON, INDEPENDIENTEMENTE ENTRE SI, HIDROGENO, (C{SUB,1} UILO O FLUOROALQUILO, O R{SUB,1} Y R{SUB,2} JUNTO CON C ORMAN UN (C{SUB,3} LO, O R{SUB,1} Y R{SUB,2} JUNTOS FORMAN = CH{SUB,2}; R{SUB,3} Y R{SUB,4} SON, INDEPENDIENTEMENTE ENTRE SI, UN (C{SUB,1} SUB,4}) ALQUILO O FLUOROALQUILO, O R{SUB,3} Y R{SUB,4} JUNTO CON C FLUOROALQUILO; A ES UN ENLACE SENCILLO O UN DOBLE ENLACE; Y B ES UN DOBLE ENLACE O UN TRIPLE ENLACE; EXCEPTO QUE DONDE R{SUB,3} Y R{SUB,4} SON CADA UNO DE ELLOS CF{SUB,3} Y A ES UN DOBLE ENLACE Y B ES UN TRIPLE ENLACE Y R{SUB,2} ES HIDROGENO, ENTONCES R{SUB,1} NOPUEDE SER CH{SUB,3}, SON UTILES EN EL TRATAMIENTO DE LA OSTEOPOROSIS.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US1821996P | 1996-05-23 | 1996-05-23 | |
| US3990197P | 1997-03-19 | 1997-03-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2195049T3 true ES2195049T3 (es) | 2003-12-01 |
Family
ID=26690870
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES97107868T Expired - Lifetime ES2195049T3 (es) | 1996-05-23 | 1997-05-14 | Analogos de vitamina d3 fluorados. |
Country Status (26)
| Country | Link |
|---|---|
| EP (1) | EP0808832B1 (es) |
| JP (1) | JP2859248B2 (es) |
| KR (1) | KR100253961B1 (es) |
| CN (1) | CN100402497C (es) |
| AR (1) | AR007776A1 (es) |
| AT (1) | ATE238278T1 (es) |
| AU (1) | AU733970B2 (es) |
| BR (1) | BR9703385A (es) |
| CA (1) | CA2205315C (es) |
| CO (1) | CO4940503A1 (es) |
| CZ (1) | CZ157797A3 (es) |
| DE (1) | DE69721123T2 (es) |
| DK (1) | DK0808832T3 (es) |
| ES (1) | ES2195049T3 (es) |
| HR (1) | HRP970272A2 (es) |
| HU (1) | HUP9700928A3 (es) |
| IL (1) | IL120844A0 (es) |
| MA (1) | MA24250A1 (es) |
| NO (1) | NO972278L (es) |
| NZ (1) | NZ314840A (es) |
| PE (1) | PE66798A1 (es) |
| PL (1) | PL320130A1 (es) |
| PT (1) | PT808832E (es) |
| SG (1) | SG70010A1 (es) |
| TR (1) | TR199700416A2 (es) |
| YU (1) | YU20097A (es) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6008209A (en) * | 1997-04-28 | 1999-12-28 | Hoffmann-La Roche Inc. | Method of using vitamin D3 analogs with bis C-20 side chains |
| DE19935771A1 (de) | 1999-07-23 | 2001-02-01 | Schering Ag | Neue Vitamin D-Derivate mit cyclischen Substrukturen in den Seitenketten, Verfahren und Zwischenprodukte zu ihrer Herstellung und die Verwendung zur Herstellung von Arzneimitteln |
| EP1314427A4 (en) * | 2000-08-17 | 2006-05-03 | Chugai Pharmaceutical Co Ltd | THERAPEUTIC AGENT FOR THE TREATMENT OF OSTEOPOROSIS |
| AU2002338672B2 (en) * | 2001-09-21 | 2006-03-09 | F. Hoffmann-La Roche Ag | 3-desoxy-vitamin D3 analog esters |
| PT103177A (pt) | 2003-09-24 | 2005-03-31 | Bioxell Spa | 1-alfa-fluoro-25-hidroxi-16,23e-dieno-26,27-bis-homo-20-epi-colecalciferol, seus sais ou esteres e sua utilizacao no fabrico de medicamentos |
| JP2008514621A (ja) * | 2004-09-24 | 2008-05-08 | ビオクセル エッセ ピ ア | ２０−シクロアルキル，２６，２７−アルキル／ハロアルキル−ビタミンｄ３化合物及びその使用方法 |
| EP1879596A4 (en) * | 2005-03-23 | 2009-01-21 | Bioxell Spa | 20 ALKYL, GEMINI VITAMIN D3 COMPOUNDS AND METHOD OF USE THEREOF |
| SG189427A1 (en) | 2010-10-25 | 2013-05-31 | Teijin Pharma Ltd | 23-yne-vitamin d3 derivative |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4141746A1 (de) * | 1991-12-13 | 1993-06-17 | Schering Ag | 20-methyl-substituierte vitamin d-derivate |
| DE4220757A1 (de) * | 1992-06-24 | 1994-01-05 | Schering Ag | Derivate in der Vitamin D-Reihe mit Modifikationen in der 20-Position, Verfahren zu ihrer Herstellung, Zwischenprodukte für dieses Verfahren, diese Derivate enthaltende pharmazeutische Präparate sowie deren Verwendung zur Herstellung von Arzneimitteln |
| US5428029A (en) * | 1993-11-24 | 1995-06-27 | Hoffmann-La Roche Inc. | Vitamin D3 fluorinated analogs |
| US5384314B1 (en) * | 1994-03-11 | 1997-08-05 | Hoffmann La Roche | 1alpha-fluoro-25-hydroxy-16-ene-23-yne-cholecalciferol |
| AU7295696A (en) * | 1995-10-27 | 1997-05-22 | F. Hoffmann-La Roche Ag | Pharmaceutical composition for treating osteoporosis |
-
1997
- 1997-05-12 SG SG1997001484A patent/SG70010A1/en unknown
- 1997-05-14 EP EP97107868A patent/EP0808832B1/en not_active Expired - Lifetime
- 1997-05-14 PT PT97107868T patent/PT808832E/pt unknown
- 1997-05-14 DE DE69721123T patent/DE69721123T2/de not_active Expired - Lifetime
- 1997-05-14 ES ES97107868T patent/ES2195049T3/es not_active Expired - Lifetime
- 1997-05-14 DK DK97107868T patent/DK0808832T3/da active
- 1997-05-14 AT AT97107868T patent/ATE238278T1/de not_active IP Right Cessation
- 1997-05-14 CA CA002205315A patent/CA2205315C/en not_active Expired - Fee Related
- 1997-05-16 IL IL12084497A patent/IL120844A0/xx unknown
- 1997-05-16 NZ NZ314840A patent/NZ314840A/en unknown
- 1997-05-16 PE PE1997000387A patent/PE66798A1/es not_active Application Discontinuation
- 1997-05-20 NO NO972278A patent/NO972278L/no unknown
- 1997-05-20 HR HR60/039,901A patent/HRP970272A2/xx not_active Application Discontinuation
- 1997-05-20 YU YU20097A patent/YU20097A/sh unknown
- 1997-05-21 MA MA24631A patent/MA24250A1/fr unknown
- 1997-05-21 HU HU9700928A patent/HUP9700928A3/hu unknown
- 1997-05-21 AR ARP970102159A patent/AR007776A1/es active IP Right Grant
- 1997-05-22 KR KR1019970020029A patent/KR100253961B1/ko not_active Expired - Fee Related
- 1997-05-22 PL PL97320130A patent/PL320130A1/xx unknown
- 1997-05-22 CO CO97028096A patent/CO4940503A1/es unknown
- 1997-05-22 CN CNB971134324A patent/CN100402497C/zh not_active Expired - Fee Related
- 1997-05-22 JP JP9131810A patent/JP2859248B2/ja not_active Expired - Fee Related
- 1997-05-22 AU AU23576/97A patent/AU733970B2/en not_active Ceased
- 1997-05-22 CZ CZ971577A patent/CZ157797A3/cs unknown
- 1997-05-23 TR TR97/00416A patent/TR199700416A2/xx unknown
- 1997-05-23 BR BR9703385A patent/BR9703385A/pt not_active Application Discontinuation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2061552T3 (es) | Productos intermedios de tetrazol para compuestos antihipertensores. | |
| DE3769735D1 (de) | Verwendung von quellfaehigen, synthetischen schichtsilikaten in waessrigen bohrspuel- und bohrlochbehandlungsmitteln. | |
| ES2123149T3 (es) | Derivados de perhidroisoindol como antagonistas de la substancia p. | |
| ES2117123T3 (es) | Derivados de aminocetilmercaptoacetilamida utilizados como inhibidores de la encefalinasa y del enzima de conversion de angiotensina. | |
| ES2148464T3 (es) | Mezcla sinergica de estabilizadores. | |
| ES2165395T3 (es) | Oxazolinas y tiazolinas artropodicidas. | |
| ATE57946T1 (de) | Schlagzaehe polyamid-formmassen. | |
| ES2124884T3 (es) | Nuevos derivados de prednisolona. | |
| ES2048109A1 (es) | Procedimiento de preparacion de nuevos derivados piperidicos del bencimidazol. | |
| ES2177952T3 (es) | Compuestos codrticoides de esteres de nitrato y su utilizacion farmaceutica. | |
| ES2195049T3 (es) | Analogos de vitamina d3 fluorados. | |
| ES2054805T3 (es) | Estabilizadores a la luz polimericos aminicos impedidos. | |
| ES2072263T3 (es) | Derivados de 4-aminopiridina. | |
| ES2110260T3 (es) | Androstenonas. | |
| ES2064729T3 (es) | Complejos de rutenio (iii) como agentes antineoplasticos. | |
| ES2076155T3 (es) | Compuestos de piperidinilo. | |
| ES2043863T3 (es) | Procedimiento para preparar derivados de la 1,2,5,6-tetrahidropiridina. | |
| ES2067628T3 (es) | Nuevo compuesto policationico y composicion blanqueante que lo contiene. | |
| ES2166900T3 (es) | Derivados de ara-c. | |
| ES8802149A1 (es) | Un procedimiento para la preparacion de derivados de piperazinilo 1,4-disustituidos | |
| GB1398993A (en) | Triazolyl-styryl compounds | |
| ATE59781T1 (de) | Potenzierung von prazosin. | |
| ES2166525T3 (es) | Procedimiento mejorado para la obtencion de halogenometilciclopropanos y halogenometilciclopropanos especialmente puros. | |
| CO4950614A1 (es) | Antagonistas de taquiquinina | |
| ES2103104T3 (es) | Nuevos compuestos di- y poliaminicos utiles en la preparacion de poliuretanos. |